Does Intraoperative Ulinastatin Improve Postoperative Clinical Outcomes in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials

Table 2

Summary of effects of ulinastatin treatment on postoperative outcomes.

Outcome	Number of studies	Total 𝑁	OR^#/MD	95% CI	P value	𝐼^2 (%)
Clinical
Hospital mortality	3	126	0.48^#	0.12 to 1.99	0.31	0
Complication rate	5	176	0.41^#	0.16 to 1.08	0.07	0
ICU stay (h)	8	318	−5.21	−11.64 to 1.21	0.11	81
Extubation time (h)	11	385	−4.18	−6.87 to −1.49	0.002	95
Physiologic
cTnI (ng/mL)	6	206	−0.97	−1.66 to −0.28	0.006	78
CKMB (ng/mL)	6	242	−3.86	−9.68 to 1.95	0.19	84
Postoperative OI	5	127	85.23	59.75 to 110.72	<0.00001	50
Postoperative CI	4	138	−0.10	−0.32 to 0.12	0.39	0
Biologic
TNF-α (pg/mL)	7	203	−49.04	−76.15 to −21.92	0.0004	86
PMNE (𝜇g/dL)	6	161	−6.86	−11.79 to −1.94	0.006	97
IL-6 (pg/mL)	8	219	−28.02	−47.95 to −8.08	0.006	85
IL-8 (pg/mL)	6	129	−20.38	−32.48 to −8.28	0.001	88

ICU: intensive care unit, POMV: postoperative mechanic ventilation, TNF-𝛼: tumor necrosis factor-alpha, PMNE: polymorphonuclear neutrophil elastase, IL-6: interleukin-6, IL-8: interleukin-8, cTnI: cardiac troponin-I, CK-MB: creatine kinase MB isoenzyme, OI: oxygenation index, CI: cardiac index, OR: odds ratios, MD: mean difference, 95% CI: 95% confidence intervals.
^#OR: odds ratio.